
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Eurand N.V. (MM) | NASDAQ:EURX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.985 | 0 | 00:00:00 |
Number of Ordinary Shares
|
|||||
Proposal
|
For
|
Against
|
Abstain
|
Broker
Non-Vote
|
|
1A
|
To appoint John J. Fraher as executive director ‘A’ and Chief Executive Officer of the Company.
|
33,222,951
|
70,403
|
0
|
0
|
1B
|
To appoint Cecilia Gonzalo as a non-executive director ‘B’ of the Company.
|
33,222,866
|
70,338
|
100
|
0
|
2A
|
To review and approve compensation for John J. Fraher, Executive Director and Chief Executive Officer of the Company.
|
33,271,507
|
21,247
|
600
|
0
|
2B
|
To review and approve compensation for Angelo C. Malahias, Chairman of the Board of the Company.
|
33,292,439
|
265
|
650
|
0
|
2C
|
To review and approve compensation for Cecilia Gonzalo as a Director of the Company.
|
33,271,522
|
21,182
|
650
|
0
|
3
|
To grant a discharge to the resigning directors (Gearoid Faherty and Jonathan Cosgrave) in respect of their management during the financial year 2010.
|
33,271,622
|
21,232
|
500
|
0
|
4
|
To approve the Share Purchase Agreement by and among the Company, Axcan Holdings Inc. and Axcan Pharma Holding B.V.
|
33,292,554
|
750
|
50
|
0
|
5
|
To review and approve the sale of all assets and liabilities of the Company to Axcan Pharma Holding B.V. or one or more of its designees, effective upon the closing of the Axcan offer.
|
33,292,554
|
700
|
100
|
0
|
6
|
To approve the designation of the Members of the Special Committee with respect to the sale of the assets and liabilities of the Company, effective upon the closing of the Axcan offer.
|
33,292,554
|
700
|
100
|
0
|
7A
|
To appoint Richard Tarte, VP, Corporate Development and General Counsel of Axcan, as an executive director ‘A’ of the Company, effective upon the closing of the Axcan offer.
|
33,267,044,
|
26,160
|
150
|
0
|
7B
|
To appoint Richard DeVleeschouwer, Senior Vice President, Human Resources of Axcan, as an executive director ‘A’ of the Company, effective upon the closing of the Axcan offer.
|
33,266,994
|
26,160
|
200
|
0
|
7C
|
To appoint Steve Gannon, Senior Vice President, CFO and Treasurer of Axcan, as an executive director ‘A’ of the Company, effective upon the closing of the Axcan offer.
|
33,266,994
|
26,160
|
200
|
0
|
8
|
To approve the dissolution of the Company, effective upon the closing of the Axcan offer.
|
33,292,102
|
1,152
|
100
|
0
|
9
|
To approve the appointment of Axcan Pharma Holding B.V. keeper of the books and records of the Company upon termination of the liquidation, effective upon the completion of the Subsequent Offering Period.
|
33,292,152
|
1,102
|
100
|
0
|
10
|
To approve any other resolution tabled in connection with the above.
|
26,594,374
|
6,698,780
|
200
|
0
|
Date: January 19, 2011
|
EURAND N.V.
|
|
By:
|
/s/ Manya S. Deehr
|
|
Manya S. Deehr
|
||
Chief Legal Officer & Secretary
|
1 Year Eurand N.V. (MM) Chart |
1 Month Eurand N.V. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions